Resultados de procura - Laure Peyro‐Saint‐Paul
- Mostrando 1 - 3 Resultados de 3
-
1
-
2
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2... por Jean‐Jacques Parienti, Thiérry Prazuck, Laure Peyro‐Saint‐Paul, Anna Fournier, Cécile Valentin, Sylvie Brucato, Renaud Verdon, Aymeric Sève, Mathilda Colin, Fabien Lesne, Jérôme Guinard, Meriadeg Ar Gouilh, Julia Dina, Astrid Vabret, Laurent Hocqueloux
Publicado 2021Artigo -
3
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study por F. Mouriaux, Vincent Servois, J J Parienti, Thierry Lesimple, A. Thyss, Caroline Dutriaux, E M Neidhart-Berard, Nicolas Penel, Corinne Delcambre, Laure Peyro‐Saint‐Paul, A.N.H. Pham, Natacha Heutte, Sophie Piperno‐Neumann, Florence Joly
Publicado 2016Artigo
Ferramentas de procura:
Materias Relacionadas
Internal medicine
Medicine
Adverse effect
Antiretroviral therapy
Human immunodeficiency virus (HIV)
Viral load
Virology
Cancer research
Cart
Chemotherapy
Clinical endpoint
Clinical trial
Confidence interval
Darunavir
Dolutegravir
Emtricitabine
Engineering
Environmental health
Hepatocellular carcinoma
Interquartile range
Mechanical engineering
Melanoma
Nursing
Odds ratio
Oncology
Phases of clinical research
Population
Progression-free survival
Quality of life (healthcare)
Raltegravir